全文获取类型
收费全文 | 5402篇 |
免费 | 563篇 |
国内免费 | 3篇 |
出版年
2023年 | 22篇 |
2022年 | 64篇 |
2021年 | 119篇 |
2020年 | 78篇 |
2019年 | 84篇 |
2018年 | 132篇 |
2017年 | 94篇 |
2016年 | 198篇 |
2015年 | 300篇 |
2014年 | 302篇 |
2013年 | 332篇 |
2012年 | 414篇 |
2011年 | 379篇 |
2010年 | 244篇 |
2009年 | 239篇 |
2008年 | 279篇 |
2007年 | 338篇 |
2006年 | 261篇 |
2005年 | 249篇 |
2004年 | 200篇 |
2003年 | 189篇 |
2002年 | 219篇 |
2001年 | 101篇 |
2000年 | 76篇 |
1999年 | 88篇 |
1998年 | 54篇 |
1997年 | 57篇 |
1996年 | 35篇 |
1995年 | 30篇 |
1994年 | 44篇 |
1993年 | 28篇 |
1992年 | 71篇 |
1991年 | 51篇 |
1990年 | 45篇 |
1989年 | 48篇 |
1988年 | 25篇 |
1987年 | 34篇 |
1986年 | 31篇 |
1985年 | 40篇 |
1984年 | 47篇 |
1983年 | 28篇 |
1982年 | 36篇 |
1981年 | 23篇 |
1980年 | 18篇 |
1979年 | 15篇 |
1978年 | 22篇 |
1977年 | 19篇 |
1975年 | 15篇 |
1974年 | 12篇 |
1973年 | 18篇 |
排序方式: 共有5968条查询结果,搜索用时 78 毫秒
891.
Abnormal protein glycosylation is observed in many common disorders like cancer, inflammation, Alzheimer’s disease and diabetes. However, the actual use of this information in clinical diagnostics is still very limited. Information is usually derived from analysis of total serum N-glycan profiling methods, whereas the current use of glycoprotein biomarkers in the clinical setting is commonly based on protein levels. It can be envisioned that combining protein levels and their glycan isoforms would increase specificity for early diagnosis and therapy monitoring. To establish diagnostic assays, based on the mass spectrometric analysis of protein-specific glycosylation abnormalities, still many technical improvements have to be made. In addition, clinical validation is equally important as well as an understanding of the genetic and environmental factors that determine the protein-specific glycosylation abnormalities. Important lessons can be learned from the group of monogenic disorders in the glycosylation pathway, the Congenital Disorders of Glycosylation (CDG). Now that more and more genetic defects are being unraveled, we start to learn how genetic factors influence glycomics profiles of individual and total serum proteins. Although only in its initial stages, such studies suggest the importance to establish diagnostic assays for protein-specific glycosylation profiling, and the need to look beyond the single glycoprotein diagnostic test. Here, we review progress in and lessons from genetic disease, and review the increasing opportunities of mass spectrometry to analyze protein glycosylation in the clinical diagnostic setting. Furthermore, we will discuss the possibilities to expand current CDG diagnostics and how this can be used to approach glycoprotein biomarkers for more common diseases. 相似文献
892.
893.
894.
895.
896.
897.
898.
Interactions of substrates at the surface of P450s can greatly enhance substrate potency 总被引:2,自引:0,他引:2
Hegde A Haines DC Bondlela M Chen B Schaffer N Tomchick DR Machius M Nguyen H Chowdhary PK Stewart L Lopez C Peterson JA 《Biochemistry》2007,46(49):14010-14017
Cytochrome P450s are a superfamily of heme containing enzymes that use molecular oxygen and electrons from reduced nicotinamide cofactors to monooxygenate organic substrates. The fatty acid hydroxylase P450BM-3 has been particularly widely studied due to its stability, high activity, similarity to mammalian P450s, and presence of a cytochrome P450 reductase domain that allows the enzyme to directly receive electrons from NADPH without a requirement for additional redox proteins. We previously characterized the substrate N-palmitoylglycine, which found extensive use in studies of P450BM-3 due to its high affinity, high turnover number, and increased solubility as compared to fatty acid substrates. Here, we report that even higher affinity substrates can be designed by acylation of other amino acids, resulting in P450BM-3 substrates with dissociation constants below 100 nM. N-Palmitoyl-l-leucine and N-palmitoyl-l-methionine were found to have the highest affinity, with dissociation constants of less than 8 nM and turnover numbers similar to palmitic acid and N-palmitoylglycine. The interactions of the amino acid side chains with a hydrophobic pocket near R47, as revealed by our crystal structure determination of N-palmitoyl-l-methionine bound to the heme domain of P450BM-3, appears to be responsible for increasing the affinity of substrates. The side chain of R47, previously shown to be important in interactions with negatively charged substrates, does not interact strongly with N-palmitoyl-l-methionine and is found positioned at the enzyme-solvent interface. These are the tightest binding substrates for P450BM-3 reported to date, and the affinity likely approaches the maximum attainable affinity for the binding of substrates of this size to P450BM-3. 相似文献
899.
900.